Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.

There was a numerical trend to flare of autoimmune disease in patients who had clinically active disease more than those who had clinically inactive disease (50% vs 29%, OR 1.59; 95% CI 0.34 to 7.38, p=0.56).

also in 1,012 other papers